PEGylation of liposome decreases the susceptibility of liposomal drug in cancer photodynamic therapy

40Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

For the purpose of the avoidance of reticuloendothelial system (RES)-trapping, liposome entrapped benzoporphyrin derivative monoacid ring A (BPD-MA), which is used for cancer photodynamic therapy (PDT), was modified with polyethylene glycol (PEG-LipBPD-MA). Tumor accumulation of BPD-MA at 3 h after injection with PEG-LipBPD-MA in Meth A-sarcoma-bearing mice was significantly higher than that after injection with non-modified liposomal BPD-MA (Cont-LipBPD-MA) as expected. On the contrary, significant tumor growth suppression after PDT was observed only for Cont-LipBPD-MA but not for PEG-LipBPD-MA. Thus, PEGylation enhances the passive targeting of liposomal BPD-MA in tumor, but decreases the susceptibility of the drug in PDT. © 2004 Pharmaceutical Society of Japan.

Cite

CITATION STYLE

APA

Ichikawa, K., Hikita, T., Maeda, N., Takeuchi, Y., Namba, Y., & Oku, N. (2004). PEGylation of liposome decreases the susceptibility of liposomal drug in cancer photodynamic therapy. Biological and Pharmaceutical Bulletin, 27(3), 443–444. https://doi.org/10.1248/bpb.27.443

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free